On September 25, 2023 Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., reported a long-term partnership to identify pre-clinical candidates against multiple oncology targets (Press release, Vernalis, SEP 25, 2023, View Source;utm_medium=rss&utm_campaign=pierre-fabre-laboratories-and-vernalis-announce-a-drug-discovery-collaboration-in-oncology [SID1234635389]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of targets and use fragment and structure-based methods to identify small molecules that modulate their activity. This research will be combined with the oncology experience of Pierre Fabre Laboratories to identify drug candidates for treatment of a range of cancers for further development and commercialisation by Pierre Fabre Laboratories. The research at Vernalis will be funded by Pierre Fabre Laboratories who will also pay research and clinical milestones and royalties on marketed products. The detailed terms of the agreement are not disclosed.

James Murray, Research Director of Vernalis said: "This strategic partnership is built on the Vernalis track record for innovation and success in enabling drug discovery and identifying clinical candidates for a wide variety of therapeutic targets. We look forward to building this long-term partnership with Pierre Fabre Laboratories, leveraging their deep expertise in cancer biology and clinical development."

Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories said: "Partnering with Vernalis represents an important milestone for us. Leveraging the expertise of Vernalis in key areas of Structure Based Drug Design to deliver high quality clinical candidates on multiple Oncology targets is a real asset to develop our Small Molecule Drug Discovery pipeline".